Viridos Sells Algae Assets to Breakthrough Energy Ventures for $5.95M

Viridos, Inc.'s chapter 11 case was dismissed in November 2025, following a 64-day sale of its algae biofuel technology to Breakthrough Energy Ventures II, L.P., the fund that had led Viridos's 2023 post-ExxonMobil financing round and then served as both DIP lender and stalking horse purchaser in the bankruptcy. Viridos, founded by genomics scientist Craig Venter as Synthetic Genomics in 2005 and based in La Jolla, California, filed for chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware on April 14, 2025 (Case No. 25-10697), after ExxonMobil ended a 14-year algae biofuel research partnership in spring 2023, having spent more than $350 million since 2009 on algae-fuel research. After the exit, Viridos raised a $25 million round led by Breakthrough Energy Ventures, with United Airlines Ventures and Chevron, before the bankruptcy filing.

Viridos initially filed as a Subchapter V small business debtor but converted to a regular chapter 11 case within three days. Breakthrough Energy Ventures II served as both DIP lender and stalking horse purchaser. ExxonMobil filed a limited objection to the sale. The sale to Breakthrough Energy Ventures II was approved in June 2025, and the case was dismissed in November 2025.

Debtor(s)	Viridos, Inc. (f/k/a Synthetic Genomics, Inc.; renamed September 2021)
Court	U.S. Bankruptcy Court, District of Delaware
Case Number	25-10697
Petition Date	April 14, 2025
Initial Filing	Subchapter V (converted to regular chapter 11 within 3 days)
Sale Order	June 17, 2025
Case Dismissed	November 26, 2025
Purchaser	Breakthrough Energy Ventures II, L.P.
DIP Facility	Breakthrough Energy Ventures II, L.P. — $6.5 million commitment ($4.25 million new money), 12% interest

Research this case with ElevenFlo

Ask the docket what happened, who is involved, and what comes next.

View case record

Viridos Sells Algae Assets to Breakthrough Energy Ventures for $5.95M

What are the key takeaways from “Viridos Sells Algae Assets to Breakthrough Energy Ventures for $5.95M”?

From Synthetic Genomics to the ExxonMobil Algae Program

Craig Venter is a genomics scientist who led an early draft sequence of the human genome and the first team to transfect a cell with a synthetic chromosome. He founded Synthetic Genomics in June 2005 with a mission to engineer microorganisms for practical applications. Based in La Jolla, California near his eponymous J. Craig Venter Institute, Synthetic Genomics initially pursued a broad portfolio: engineering algae, bacteria, and other organisms to produce biofuels, vaccines, and industrial chemicals.

By engineering algae strains with enhanced lipid (oil) production, Synthetic Genomics aimed to develop renewable fuel pathways for aviation and other sectors. Biofuels derived from photosynthetic algae offer up to 98% emission savings compared to petroleum-based fuels.

The ExxonMobil partnership. In July 2009, ExxonMobil announced a $600 million collaboration with Synthetic Genomics to develop next-generation biofuels from photosynthetic algae. In 2017, ExxonMobil and Synthetic Genomics published research in Nature Biotechnology demonstrating a modified Nannochloropsis gaditana strain that more than doubled oil content—from 20% to over 40%—without significantly inhibiting growth. A 2018 announcement targeted 10,000 barrels of algae biofuel per day by 2025, including outdoor field studies in California.

ExxonMobil's algae spending extended beyond Synthetic Genomics. The company funded algae research at the Colorado School of Mines and struck a $100 million, 10-year agreement with NREL in 2019. Since 2009, ExxonMobil invested over $350 million on projects developing fuel from lipids in algae.

Rebranding to Viridos. In September 2021, Synthetic Genomics rebranded as Viridos, a name derived from the Latin "viridis" meaning green. The rebranding coincided with a pivot toward the sustainable aviation fuel (SAF) market, narrowing focus from broad biofuels applications to aviation-specific solutions. The EU's ReFuelEU Aviation regulation established minimum 2% sustainable aviation fuel requirements by 2025, rising to 70% by 2050. The UK established targets requiring at least 2% SAF by 2025, 10% by 2030, and 22% by 2040.

ExxonMobil Exit and the BEV-Led Capital Raise

In spring 2023, ExxonMobil ended its 14-year algae biofuels partnership with Viridos. An ExxonMobil spokesperson said the company had invested hundreds of millions of dollars and cited peer-reviewed scientific results, but said algae had not reached the commercial and global scale ExxonMobil required. ExxonMobil shifted focus to carbon capture and hydrogen, areas where Inflation Reduction Act subsidies offered more immediate returns. The exit also ended ExxonMobil funding for projects at the Colorado School of Mines and the National Renewable Energy Laboratory.

Within a month of ExxonMobil's announcement, Viridos closed a $25 million round backed by Breakthrough Energy Ventures, United Airlines Ventures, and Chevron. The round was smaller than ExxonMobil's annualized funding and brought together climate-focused investors and aviation-industry stakeholders. The financing was intended to support research and development to scale algae-oil production for sustainable aviation and diesel fuels.

Breakthrough Energy Ventures, founded by Bill Gates in 2015, led the round. BEV I launched in 2016 with $1 billion in commitments, followed by BEV II with $1.25 billion and BEV III with $839 million raised as of 2024. The fund's 20-year investment horizon contrasts with typical 5-year venture timelines.

United Airlines Ventures participated through United's Sustainable Flight Fund, launched in February 2023 with over $100 million and including Air Canada, Boeing, GE Aerospace, JPMorgan Chase, and Honeywell. The fund subsequently grew to exceed $200 million, adding Air New Zealand, Google, and Safran.

Chevron Technology Ventures, through its Future Energy Funds, had invested in over 30 climate technology companies. Future Energy Fund III committed $500 million in 2024, following $400 million across the first two funds.

The commercialization gap. The global algae biofuel market reached $9.1 billion in 2023, growing at 10.3% annually, with projections reaching $24.3 billion by 2033. The algae-based SAF segment represented about 21% ($1.94 billion) in 2024. Those projections reflect market forecasts rather than current commercial production. Meanwhile, Hydroprocessed Esters and Fatty Acids (HEFA) technology, using used cooking oil and animal fats, accounted for the bulk of SAF production reaching commercial scale.

Subchapter V Filing and Three-Day Conversion

On April 14, 2025, Viridos filed for chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. The company initially elected Subchapter V status, the streamlined reorganization process created in 2019 for small business debtors. Subchapter V provides cost-effective restructuring for businesses with aggregate noncontingent, liquidated secured and unsecured debts not exceeding approximately $3 million (adjusted periodically), requires plans to be filed within 90 days, and permits only the debtor to propose a plan.

The Subchapter V election proved short-lived. On April 16, 2025, the court appointed Natasha Songonuga as Subchapter V Trustee. The following day, Viridos filed an amended petition removing the case from Subchapter V, converting to a regular chapter 11 proceeding.

Prepetition capital structure. Viridos's only funded debt was a secured note held by BEV II. BEV extended an initial $2 million secured convertible promissory note in July 2024, then amended and restated it to $2.75 million on April 8, 2025, leaving $2.25 million outstanding as of the petition date. The company also carried approximately $3 million in unsecured trade debt, including unpaid rent.

DIP financing structure. Breakthrough Energy Ventures II, L.P. stepped in as debtor-in-possession lender. The DIP motion was filed on April 15, 2025, accompanied by declarations from CEO Brian Ayers and CFO Eric Moellering detailing the company's financial position and need for liquidity. The court entered an interim DIP order on April 17, 2025, followed by a final DIP order on May 8, 2025, providing a $6.5 million commitment, including $4.25 million in new money, priced at 12% interest, rising to 15% on default, with $133,000 closing and exit fees and priming, superpriority liens on the debtor's assets. BEV II, a prepetition investor, paired the DIP role with its position as stalking horse bidder in the 363 sale.

Key professionals and first day relief. Womble Bond Dickinson (US) LLP served as debtor's counsel, Rock Creek Advisors, LLC as financial advisor and sales agent, and Stretto, Inc. as claims and noticing agent. The debtor filed first day motions on April 14-15, 2025, seeking relief for cash management, utilities, employee wages, and bank accounts. The court entered interim orders on April 17, 2025, followed by final orders on May 7-8, 2025. A Key Employee Incentive Plan filed under seal was approved on May 7, 2025. Ordinary course professionals retained included Tonkon Torp LLP, Lavine Lofgren Morris & Engelberg LLP, DLA Piper LLP, Wilson Turner Kosmo LLP, and Sheppard Mullin Richter & Hampton LLP.

363 Sale to Breakthrough Energy Ventures II

The sale process followed a 64-day timeline from petition to sale order. Breakthrough Energy Ventures II, L.P. entered as stalking horse bidder. On April 17, 2025, the debtor filed its bidding procedures motion, accompanied by declarations from CEO Brian Ayers, CFO Eric Moellering, and BEV Venture Partner Daniel Leff. The bidding procedures order was entered on May 8, 2025. A notice of sale by auction published May 12, 2025 invited potential competing bidders. The sale order authorizing the sale to BEV II was entered June 17, 2025. BEV II's winning bid consisted of a $5.95 million credit bid of its DIP claim under section 363(k) of the Bankruptcy Code, plus assumption of certain liabilities and payment of cure amounts, rather than a cash purchase price.

Key Date	Event
April 14, 2025	Chapter 11 Petition Filed
April 17, 2025	Bidding Procedures Motion Filed
May 8, 2025	Bidding Procedures Order Entered
May 12, 2025	Notice of Sale by Auction Published
June 2, 2025	ExxonMobil Limited Objection Filed
June 17, 2025	Sale Order Entered

ExxonMobil's limited objection. ExxonMobil Technology and Engineering Company filed a limited objection to the proposed sale on June 2, 2025. The objection did not prevent the sale from proceeding, and the sale order entered fifteen days later.

HCP Lease Resolution and Case Dismissal

HCP Life Science REIT, Inc. held a landlord claim against the estate. Life science real estate has become an increasingly challenged sector, with biotech tenant distress driving vacancy rates to 24% in San Francisco, 27% in Boston, and 17% in San Diego. HCP filed an administrative expense motion on August 11, 2025, seeking payment for post-petition lease obligations. The claim was resolved through a stipulation, with the order approving the stipulation entered on September 26, 2025. The debtor filed multiple omnibus motions to reject leases and executory contracts, beginning with the first omnibus rejection motion on May 31, 2025 and continuing through September 2025.

Following sale consummation, the debtor moved to dismiss the chapter 11 case on September 10, 2025. An initial dismissal order was entered on September 26, 2025, with a final dismissal order entered on November 26, 2025. With substantially all assets sold to BEV II, no reorganization was contemplated. The estate wound down administrative matters, resolved the HCP landlord claim, and obtained approval of professional fee applications before dismissal. The Omnibus Final Fee Order was entered on November 3, 2025, approving final compensation for Womble Bond Dickinson and Rock Creek Advisors. The debtor's final monthly operating report showed $6.2 million in total assets against $3.6 million in total liabilities as of November 26, 2025. The case lasted approximately seven and a half months from petition to final dismissal.

Algae Biofuels Industry and Climate Tech Funding

Viridos's bankruptcy added to a list of algae biofuel ventures that did not reach commercial fuel production. Solazyme (later TerraVia) raised over $200 million and went public before pivoting away from fuels toward specialty chemicals and cosmetics, and eventually filed for bankruptcy in 2017. Sapphire Energy attracted over $100 million in funding, including from Bill Gates' Cascade Investment, before selling to agricultural company Cargill. Algenol, Joule Unlimited, and others consumed substantial investment without achieving commercial fuel production.

Government funding for algae research continues. The DOE announced $20.2 million in funding for university and industry projects advancing mixed algae development. The EU-funded FUELGAE project, a four-year €5 million initiative coordinated by Spain's CSIC, seeks to develop novel methods for producing aviation fuels from algae.

Viridos's bankruptcy occurred during a multi-year climate tech venture capital contraction. Venture capital investment in climate tech declined globally for the third consecutive year, dropping from $25.9 billion in 2022 to $19.7 billion in 2023, and to $17 billion in 2024—a 34% decrease over two years. U.S. pre-seed and seed deal counts dropped from 246 to 152. Climate tech financing broadly decreased 29% from $79 billion between Q4 2022 and Q3 2023 to $56 billion in the following four quarters. Venture deal counts in clean energy reached 382 in 2024, but the sector's 12% funding increase to $9.4 billion concentrated in proven technologies rather than deep research.

Frequently Asked Questions

What happened to Viridos?

Viridos, the algae biofuels company founded by genomics scientist Craig Venter under the name Synthetic Genomics, filed chapter 11 in Delaware on April 14, 2025. ExxonMobil ended the 14-year research partnership in spring 2023 after investing more than $350 million in algae-fuel research since 2009. Breakthrough Energy Ventures II, a climate investment fund associated with Bill Gates, acquired the company's assets through a 363 sale in June 2025. The case was dismissed in November 2025.

Why did ExxonMobil end its algae biofuels partnership with Viridos?

ExxonMobil ended the partnership in 2023 after 14 years of research and more than $350 million invested since 2009, saying algae had not reached the commercial and global scale it required. The company shifted its low-carbon technology focus to hydrogen and carbon capture, areas where Inflation Reduction Act subsidies offered more immediate commercial potential. ExxonMobil said the research produced peer-reviewed scientific advances but had not reached the level necessary for commercial and global scale.

Who bought Viridos in bankruptcy?

Breakthrough Energy Ventures II, L.P. acquired Viridos's assets through a 363 sale approved on June 17, 2025. Breakthrough Energy Ventures, part of Bill Gates' Breakthrough Energy climate investment initiative, joined a $25 million financing round alongside United Airlines Ventures and Chevron following ExxonMobil's 2023 exit. BEV II served as both DIP lender and stalking horse purchaser in the bankruptcy.

Was Viridos a Subchapter V case?

Viridos initially filed as a Subchapter V small business debtor on April 14, 2025, but converted to a regular chapter 11 case within three days. The amended petition removing the case from Subchapter V was filed on April 17, 2025.

Who is the claims agent for Viridos?

Stretto, Inc. serves as the claims and noticing agent for the Viridos case. The firm maintained the official claims register throughout the proceedings, which concluded with the case's dismissal in November 2025.

What happened to ExxonMobil's objection to the sale?

ExxonMobil Technology and Engineering Company filed a limited objection to the proposed sale on June 2, 2025, fifteen days before the sale order was entered. The objection did not prevent the sale, and the sale order authorizing BEV II's acquisition was entered on June 17, 2025.

For related coverage, see Ambri's 363 sale and liquidating plan, Lipella Pharmaceuticals' biotech IP sale, and Solar Biotech's asset sale and liquidation trust.